Takahiro Yamazaki Selected Research

Death Domain Receptors

1/2021

Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takahiro Yamazaki Research Topics

Disease

48	Neoplasms (Cancer) 01/2021 - 01/2003
8	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2014
6	Carcinoma (Carcinomatosis) 01/2021 - 06/2013
4	Inflammation (Inflammations) 01/2022 - 01/2020
4	Melanoma (Melanoma, Malignant) 10/2019 - 11/2015
2	Dementia (Dementias) 05/2022 - 11/2020
2	Disease Progression 01/2021 - 01/2020
2	Triple Negative Breast Neoplasms 01/2021 - 01/2021
2	Bites and Stings (Sting) 10/2020 - 01/2019
2	Hepatocellular Carcinoma (Hepatoma) 04/2020 - 07/2012
2	Stroke (Strokes) 01/2020 - 02/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2019 - 01/2019
2	Leukemia 01/2017 - 05/2012
2	Neoplasm Metastasis (Metastasis) 03/2016 - 01/2003
1	Alzheimer Disease (Alzheimer's Disease) 05/2022
1	Dystonia (Limb Dystonia) 05/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2022
1	Wrist Fractures 11/2021
1	Hyperglycemia 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021
1	Cognitive Dysfunction 11/2020
1	Asthenopia (Eyestrain) 07/2020
1	Insulin Resistance 01/2020
1	Carcinogenesis 01/2020
1	Ischemia 01/2020
1	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2019
1	Polyploidy 11/2017

Drug/Important Bio-Agent (IBA)

9	AnthracyclinesIBA 06/2016 - 07/2012
7	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2016
5	Peptides (Polypeptides)IBA 01/2021 - 01/2016
5	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 06/2013
5	Interferon Type IIBA 10/2020 - 11/2014
4	Adenosine Triphosphate (ATP)IBA 01/2021 - 04/2013
4	Hormones (Hormone)IBA 01/2021 - 01/2020
4	Biomarkers (Surrogate Marker)IBA 04/2020 - 01/2019
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2016 - 07/2012
3	Cytostatic AgentsIBA 01/2021 - 01/2019
3	CytokinesIBA 01/2021 - 05/2012
3	CarcinogensIBA 01/2021 - 09/2012
3	Phenobarbital (Luminal)FDA Link 01/2021 - 01/2020
3	AntigensIBA 01/2020 - 01/2016
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2016 - 11/2013
3	InterferonsIBA 02/2016 - 08/2015
2	Retinaldehyde (Retinal)IBA 01/2022 - 01/2020
2	Food IngredientsIBA 11/2020 - 01/2020
2	Indicators and Reagents (Reagents)IBA 07/2020 - 05/2012
2	theasinensin AIBA 01/2020 - 01/2019
2	CrizotinibIBA 04/2019 - 01/2019
2	Caspase 3 (Caspase-3)IBA 01/2019 - 06/2016
2	AntibodiesIBA 01/2019 - 11/2015
2	HMGB1 Protein (HMG1)IBA 01/2019 - 06/2016
2	CalreticulinIBA 01/2019 - 09/2012
2	VaccinesIBA 01/2019 - 07/2012
2	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 09/2012
2	ChemokinesIBA 03/2016 - 09/2015
2	Chemokine ReceptorsIBA 03/2016 - 09/2015
2	Anti-Bacterial Agents (Antibiotics)IBA 11/2015 - 11/2013
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2013 - 01/2008
1	brexpiprazoleIBA 05/2022
1	Quetiapine Fumarate (Seroquel)FDA Link 05/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	LipopolysaccharidesIBA 01/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	ElementsIBA 11/2021
1	Estrogen ReceptorsIBA 01/2021
1	LTX-315IBA 01/2021
1	palbociclibIBA 01/2021
1	EpitopesIBA 01/2021
1	Histocompatibility Antigens Class IIIBA 01/2021
1	ApolipoproteinsIBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	Cyclin-Dependent Kinase 4IBA 01/2021
1	Death Domain ReceptorsIBA 01/2021
1	AcidsIBA 11/2020
1	Mitochondrial DNA (mtDNA)IBA 10/2020
1	Triglycerides (Triacylglycerol)IBA 04/2020
1	InflammasomesIBA 01/2020
1	Uric Acid (Urate)IBA 01/2020
1	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2020
1	anthraceneIBA 01/2020
1	diphosphoric acid (pyrophosphoric acid)IBA 01/2020
1	PlatinumIBA 01/2020
1	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 01/2020
1	Nitric Oxide Synthase (NO Synthase)IBA 10/2019
1	Monoclonal AntibodiesIBA 10/2019
1	CaspasesIBA 01/2019
1	EnzymesIBA 01/2019
1	Blocking AntibodiesIBA 01/2019
1	LTX-401IBA 01/2019
1	Cisplatin (Platino)FDA LinkGeneric 01/2019
1	Methoxsalen (Oxsoralen)FDA Link 01/2019
1	TNF Receptor-Associated Factor 1IBA 01/2018
1	Type II Tumor Necrosis Factor ReceptorsIBA 01/2018
1	Histocompatibility Antigens Class IIBA 11/2017

Therapy/Procedure

17	Therapeutics 01/2021 - 04/2013
10	Immunotherapy 01/2021 - 05/2012
9	Radiotherapy 01/2021 - 11/2017
9	Drug Therapy (Chemotherapy) 11/2020 - 10/2010
1	Injections 01/2019
1	Photopheresis 01/2019